Sweden’s TLV has published its health economic assessment of Merck’s Keytruda for locally advanced cervical cancer, finding clear efficacy benefits when added to chemoradiation. However, the agency warns that cost-effectiveness hinges on price transparency and real-world survival durability.
CMS’ Medicaid drug payment model links value-based pricing and international benchmarks to lower costs and improve patient outcomes. (Editorial illustration.) US government aims to lower Medicaid drug prices and align costs with global rates under new GENEROUS model The US government has launched a sweeping initiative to reduce prescription drug costs under the Medicaid program, … Read more
The Dutch Healthcare Institute is taking a cautious, phased approach to new obesity drugs, limiting access to patients with the highest disease burden. The move reflects concerns about evidence gaps, cost-effectiveness, and the growing pressure obesity treatments could place on the national healthcare budget.
Thailand is letting patients fill hospital prescriptions at registered pharmacies under a new initiative expected to save households 32 billion baht annually. Officials say the program will ease private-sector pricing pressure and improve drug access nationwide.
In a major policy moment, Lilly and Novo Nordisk are in active talks with U.S. officials to cap obesity drug prices, aligning political pressure with market strategy.
HRSA’s approval of eight manufacturers for its 340B Rebate Model Pilot signals a major pricing shift.
CMS’s payment modernization plan seeks to trim inefficiencies, curb wasteful spending in wound care, and realign value in Medicare reimbursement. Providers brace for tighter margins as policymakers hail a new era of cost discipline.
From October 27, 2025, patients in the Netherlands with spinal metastases or multiple myeloma can access bone cement injections.
ICER pegs an ~$88K benchmark for brensocatib and spotlights evidence gaps shaping NCFB access.
In a transformative week for market access, the CMS and Europe reimbursement pathway expansion delivered several pivotal coverage and pricing decisions reshaping patient access across cardiovascular, hepatic, and oncology therapies. From CMS’s national determinations on breakthrough devices to European HTA approvals in rare disease and cancer, these developments underscore a growing transatlantic alignment between regulators … Read more